GLP-1 Inhibitors vs Agonists: Clearing Up the Confusion

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article lives in the PlexusDx Education Hub, where we work through GLP-1 biology, weight-management protocols, and the genetic factors that sit beneath every metabolic decision. Browse the full Peptides & GLP-1 library.

"GLP-1 inhibitors" is one of the more common phrases people search, and it points to a genuine mix-up. The medications built around this hormone activate a receptor rather than block one, which makes "inhibitor" the wrong label. This article untangles the terminology, explains what GLP-1 is, describes how the real drug class works, lists what is approved, and covers the genetics that sit upstream of any decision.

Clearing up the terminology first

The drugs commonly meant by this search are GLP-1 receptor agonists. An agonist switches a receptor on; an inhibitor blocks activity. These medications engage the GLP-1 receptor to reproduce the hormone's effects, so calling them inhibitors reverses their actual mechanism. A separate class, DPP-4 inhibitors, does block an enzyme, which is likely where some of the confusion originates.

What GLP-1 actually is

Native GLP-1 is a 30- to 31-amino-acid peptide secreted by intestinal L-cells. Once released it stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release, slows gastric emptying, and engages central satiety circuits in the hypothalamus. Its natural half-life is very short, roughly two minutes, because the enzyme dipeptidyl peptidase-4 (DPP-4) degrades it quickly.

How the receptor-agonist drugs work

GLP-1 receptor agonist medications are engineered to resist DPP-4 degradation, extending the half-life from minutes to days or weeks. They bind the same receptor as the native hormone, driving the same downstream effects on insulin secretion, glucagon suppression, gastric emptying, and satiety. Tirzepatide-based compounds add agonism at the GIP receptor, a related incretin target, which is one of the key molecular distinctions in the class as of April 2026.

What is approved as of April 2026

The FDA-approved class includes exenatide (Byetta, 2005; Bydureon), liraglutide (Victoza, 2010; Saxenda, 2014), dulaglutide (Trulicity, 2014), semaglutide (Ozempic, 2017; Rybelsus, 2019; Wegovy, 2021), and tirzepatide (Mounjaro, 2022; Zepbound, 2023; Zepbound expanded to obstructive sleep apnea in 2024). Investigational compounds in late-stage development include retatrutide, a GIP/GLP-1/glucagon triple agonist that is not FDA-approved and not sold by PlexusDx, and orforglipron, an oral non-peptide small-molecule agonist.

How these medications are taken

Most approved GLP-1 receptor agonists are given as subcutaneous injections, weekly or daily depending on the compound. Rybelsus is the only FDA-approved oral option as of April 2026. Compounded oral protocols exist through licensed compounding pharmacy pathways, though these are not FDA-approved branded products.

Why genetics shape the pathway

The GLP-1 pathway carries natural genetic variation. GLP1R, the receptor gene itself, is the most direct upstream variable, influencing receptor density and downstream signaling efficiency. FTO shapes appetite and adiposity set-point, MC4R influences hypothalamic satiety and total intake, and TCF7L2 affects insulin secretion and incretin response. These are pathway-level markers, not predictors of any one compound's effect. The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights as educational context, and it does not tell you which medication or dose to choose. PlexusDx offers GLP-1 receptor agonists through its Weight Management Protocols.

Why the naming matters beyond semantics

Getting the terminology right is not pedantry; it changes what you expect a medication to do. An agonist and an inhibitor sit at opposite ends of pharmacology, so mislabeling the class can lead to genuine misunderstanding about mechanism, effects, and even which conversations to have with a provider. Anchoring on the correct term, receptor agonist, keeps the rest of the picture, from side effects to administration, logically consistent.

Where DPP-4 inhibitors fit

The confusion often traces back to a real class that does inhibit something. DPP-4 inhibitors block the enzyme that breaks down native GLP-1, indirectly raising the body's own hormone levels, whereas receptor agonists bind and activate the receptor directly. The two approaches differ in mechanism and in how they are used. If you encounter both terms and are unsure which applies to your situation, a provider can clarify exactly what has been recommended and why, so the plan rests on an accurate understanding rather than a mixed-up label.

Frequently Asked Questions

Are GLP-1 inhibitors a real drug class?

Not in the way the phrase suggests. The medications people mean are GLP-1 receptor agonists, which activate the receptor rather than block it. There is no widely used class called GLP-1 inhibitors in current practice. DPP-4 inhibitors are a separate class that reduces breakdown of native GLP-1.

What does GLP-1 stand for?

GLP-1 stands for glucagon-like peptide-1, an incretin hormone secreted by intestinal L-cells in response to food intake. Once released, it stimulates glucose-dependent insulin release, slows gastric emptying, and signals satiety to the brain. The receptor-agonist drug class is designed to reproduce these same effects pharmacologically and at a longer duration.

Does genetic testing tell me which GLP-1 to take?

No. The Precision Peptide Genetic Test reports pathway-level variants in GLP1R, FTO, MC4R, and other genes that shape baseline GLP-1 biology. It does not predict which medication is right for anyone and it does not tell you which medication or dose to choose. It is context for the broader conversation with a provider.

Related reading: GLP-1 Receptor Agonist, The GLP-1 Hormone, GLP-1 Drugs.

Keep reading across the PlexusDx Education Hub. Return to all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.